Every material Form 8-K Innoviva filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Innoviva reported third-quarter 2023 results, furnished in a press release as Exhibit 99.1. Total revenue of $67.3 million was essentially unchanged from a year earlier, but net income fell to $82.0 million from $265.5 million, mainly because a 2022 gain on the sale of a subsidiary did not recur. Basic earnings per share were $1.26 versus $3.81, and the company repurchased $11.0 million of common stock during the quarter.
Total revenue was $67.3 million in Q3 2023, compared with $67.3 million in Q3 2022.
Net income was $82.0 million, or $1.26 basic per share, versus $265.5 million, or $3.81 basic per share, in Q3 2022.
The decline was primarily driven by a non-repeated gain on the sale of Theravance Respiratory Company and its TRELEGY ELLIPTA royalty stream in July 2022.
Innoviva repurchased $11.0 million of common stock; cash and cash equivalents totaled $180.0 million as of September 30, 2023.
Innoviva, Inc. announced that Stephen Basso has been appointed Chief Financial Officer, effective August 21, 2023. Basso previously served as CFO and Chief Operating Officer at Cybrexa Therapeutics and has more than 30 years of financial services and pharmaceutical industry experience, and the filing discloses his offer terms, including a $450,000 base salary, a 40% target bonus and an initial option grant of 150,000 shares subject to board approval.
Effective date of August 21, 2023; appointment announced August 25, 2023 in an 8-K and press release
Base salary of $450,000 and annual discretionary bonus with a 40% target of base salary
Initial grant of options to purchase 150,000 shares, subject to Board or Compensation Committee approval, plus a one-time $100,000 signing bonus
If terminated without cause or for good reason, 12 months of base salary continuation and accelerated vesting of unvested options if within 12 months after a change in control
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Innoviva filing is on SEC EDGAR ↗. 8-K briefs of other companies →